Should I Buy MGX? MGX 2026 Analysis

Should You Buy Metagenomi Therapeutics Inc (MGX) Today? Analysis, Price Targets, and 2026 Outlook.

No data

Growth

Profitability

Efficiency

4 Analyst Rating

Wall Street analysts forecast MGX stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.400

Low

Averages

8.67

High

Current: 1.400

Low

Averages

8.67

High

Wells Fargo

Overweight

downgrade

$12 -> $9

AI Analysis

2026-05-12

Reason

Wells Fargo

Price Target

$12 -> $9

AI Analysis

2026-05-12

downgrade

Overweight

Reason

Wells Fargo lowered the firm's price target on Metagenomi to $9 from $12 and keeps an Overweight rating on the shares. Following the company's Q1 update, the firm notes that MGX-001 for Hemophilia A continues to progress on track, with an IND filing anticipated in Q4 2026 and initiation of a Phase 1/2 trial in 2027.

Chardan

Geulah Livshits

Buy

downgrade

$11 -> $7

2025-11-12

Reason

Chardan

Geulah Livshits

Price Target

$11 -> $7

2025-11-12

downgrade

Buy

Reason

Chardan analyst Geulah Livshits lowered the firm's price target on Metagenomi to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MGX

Unlock Now

MGX Should I Buy

MGX Should I Buy

Should You Buy Metagenomi Therapeutics Inc (MGX) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch